Medical Management of Stable Coronary Artery Disease

被引:0
作者
Pflieger, Matthew [1 ]
Winslow, Bradford T. [2 ,3 ]
Mills, Kyle [5 ]
Dauber, Ira M. [4 ]
机构
[1] Clin Family Hlth Serv, Denver, CO 80221 USA
[2] Swedish Family Med Residency Program, Littleton, CO USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] S Denver Cardiol Associates, Denver, CO USA
[5] Bend Mem Clin, Bend, OR USA
关键词
CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; HIGH-RISK; SECONDARY PREVENTION; HEART-DISEASE; BETA-BLOCKERS; METAANALYSIS; MORTALITY; EFFICACY;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
All patients with stable coronary artery disease require medical therapy to prevent disease progression and recurrent cardiovascular events. Three classes of medication are essential to therapy: lipid-lowering, antihypertensive, and antiplatelet agents. Lipid-lowering therapy is necessary to decrease low-density lipoprotein cholesterol to a target level of less than 100 mg per dL, and physicians should consider a goal of less than 70 mg per dL for very high-risk patients. Statins have demonstrated clear benefits in morbidity and mortality in the secondary prevention of coronary artery disease; other medications that can be used in addition to statins to lower cholesterol include ezetimibe, fibrates, and nicotinic acid. Blood pressure therapy for patients with coronary artery disease should start with beta blockers and angiotensin-converting enzyme inhibitors. If these medications are not tolerated, calcium channel blockers or angiotensin receptor blockers are acceptable alternatives. Aspirin is the first-line antiplatelet agent except in patients who have recently had a myocardial infarction or undergone stent placement, in which case clopidogrel is recommended. Anginal symptoms of coronary artery disease can be treated with beta blockers, calcium channel blockers, nitrates, or any combination of these. Familiarity with these medications and with the evidence supporting their use is essential to reducing morbidity and mortality in patients with coronary artery disease. (Am Fam Physician. 2011;83 (7):819-826. Copyright (C) 2011 American Academy of Family Physicians.)
引用
收藏
页码:819 / 826
页数:8
相关论文
共 40 条
[1]  
[Anonymous], 2002, **DROPPED REF**
[2]  
Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71
[3]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[4]   The primary and secondary prevention of coronary artery disease [J].
Becker, Richard C. ;
Meade, Thomas W. ;
Berger, Peter B. ;
Ezekowitz, Michael ;
O'Connor, Christopher M. ;
Vorchheimer, David A. ;
Guyatt, Gordon H. ;
Mark, Daniel B. ;
Harrington, Robert A. .
CHEST, 2008, 133 (06) :776S-814S
[5]   Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis [J].
Berger, Jeffrey S. ;
Brown, David L. ;
Becker, Richard C. .
AMERICAN JOURNAL OF MEDICINE, 2008, 121 (01) :43-49
[6]   Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events [J].
Bhatt, DL ;
Fox, KAA ;
Hacke, W ;
Berger, PB ;
Black, HR ;
Boden, WE ;
Cacoub, P ;
Cohen, EA ;
Creager, MA ;
Easton, JD ;
Flather, MD ;
Haffner, SM ;
Hamm, CW ;
Hankey, GJ ;
Johnston, SC ;
Mak, KH ;
Mas, JL ;
Montalescot, G ;
Pearson, TA ;
Steg, PG ;
Steinhubl, SR ;
Weber, MA ;
Brennan, DM ;
Fabry-Ribaudo, L ;
Booth, J ;
Topol, EJ ;
Frye, RL ;
Amarenco, P ;
Brass, LM ;
Buyse, M ;
Cohen, LS ;
DeMets, DL ;
Fuster, V ;
Hart, RG ;
Marler, JR ;
McCarthy, C ;
Schoemig, A ;
Lincoff, AM ;
Brener, SJ ;
Sila, CA ;
Albuquerque, A ;
Aroutiounov, G ;
Artemiev, D ;
Atkeson, BG ;
Bartel, T ;
Basart, DCG ;
Lima, AB ;
Belli, G ;
Bordalo e Sa, AL ;
Bosch, X .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (16) :1706-1717
[7]   Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) :1512-1524
[8]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[9]  
Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
[10]   Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial [J].
Dickstein, K ;
Kjekshus, J .
LANCET, 2002, 360 (9335) :752-760